INTRODUCTION {#s1}
============

About one in five breast cancer patients test negative for the estrogen, progesterone, and Her2 receptors in their tumor tissues. The diagnosis of triple-negative breast cancer (TNBC) is associated with a higher recurrence rate and a less favorable prognosis than receptor-positive breast cancer. About 10% of younger patients with TNBC have a germline *BRCA1* risk variant for contralateral breast cancer and ovarian cancer ([@MEIBNERMCS001677C45]). Breast cancer patients with a familial history of cancer or who are young are increasingly being offered genetic counseling and testing for germline risk variants in *BRCA1*, *BRCA2*, *TP53*, and other genes. Patients with germline *BRCA* risk variants are then offered bilateral mastectomy. Patients without germline *TP53* risk variants may be offered adjuvant radiotherapy, whereas germline *TP53* risk variant carriers may be at an increased risk for radiation induced secondary cancers. In addition to germline testing, breast cancer tissue testing is increasingly being proposed to match approved cancer drugs with the patient\'s individual somatic mutations or gene expression profile ([@MEIBNERMCS001677C62]; [@MEIBNERMCS001677C33]).

After the initial diagnosis, the now deceased TNBC patient was tested for *BRCA1*, *BRCA2*, and *TP53* germline risk variants when she underwent standard treatments. After segmentectomy, relapse, bilateral mastectomy, and completing the last line of standard treatments, the patient decided to undergo additional experimental off-label therapy. Her treatments, which included bortezomib, eribulin, and pembrolizumab, are summarized in [Figure 1](#MEIBNERMCS001677F1){ref-type="fig"}. Whole-exome sequencing was performed on peripheral blood (PB), primary tumor (PT), and a metastasis (MK), after standard treatments failed. Whole-exome sequencing was chosen to allow the analysis of ∼90% of all genomic protein coding regions, giving a much more complete scientific and potential clinical data yield than gene panel testing. Two years later, RNA and whole-exome sequencing were performed on a fine needle aspirate of a metastasis (MF) taken at the final stage of the disease. Detailed somatic mutation analysis was performed but interpretation could not be completed until postmortem. The mutational signatures ([Fig. 2](#MEIBNERMCS001677F2){ref-type="fig"}) were associated with defective DNA mismatch repair, which nowadays would probably trigger immunotherapy ([@MEIBNERMCS001677C29]).

![Patient history. Time line in months summarizing surgical procedures, diagnoses, drug treatments, adverse events, and molecular findings. Previously reported associations with gene variants/mutations are shown in red, and associations with gene expression are shown in green. Time line colors and boxes are yellow for germline, red for ancestral tumor cell, blue for mv2 (see Fig. 3), brown for primary tumor, lilac for first metasis (MK), gray for final metasis (MF), and orange for unsampled terminal tumor clones. Gene names are in italics, up-regulation is shown by an arrow, *PSM* members *PSMB1* and *PSMB5* of the proteasome family. tox, toxicity; mets, metastases; p53mut, mutated p53.](MeibnerMCS001677_F1){#MEIBNERMCS001677F1}

![Somatic signatures. Pie charts showing the weights of each Catalogue of Somatic Mutations in Cancer (COSMIC) somatic signature assigned for the samples primary tumor (*A*), MK (*B*), and MF (*C*). Signature 1: aging (i.e., the result of an endogenous mutational process initiated by spontaneous deamination of 5-methylcytosine). Signature 3: found in breast, ovarian, and pancreatic cancers. It is associated with failure of DNA double-strand break repair by homologous recombination. It is strongly associated with germline and somatic *BRCA1* and *BRCA2* mutations in breast, pancreatic, and ovarian cancers. In pancreatic cancer, responders to platinum therapy usually exhibit Signature 3 mutations. Signature 5: found in all cancer types and most cancer samples. Etiology is unknown. Signature 6: associated with defective DNA mismatch repair and found in microsatellite unstable tumors. Signature 7: likely due to ultraviolet light exposure. Signature 12: usually contributes a small percentage (\<20%) of the mutations observed in a liver cancer sample. Signature 15: associated with defective DNA mismatch repair. Signature 26: believed to be associated with defective DNA mismatch repair. Signature 29: has been observed only in gingivo-buccal oral squamous cell carcinoma, pattern of C\>A mutations due to tobacco chewing.](MeibnerMCS001677_F2){#MEIBNERMCS001677F2}

The mutations furthermore allowed us to infer tumor evolution and an ancestral tumor cell ([Fig. 3](#MEIBNERMCS001677F3){ref-type="fig"}), which may have been of interest for treatment decisions, for diagnostic surveillance, and for the patient\'s own interest in understanding her disease. We analyzed germline pharmacogenomic variants in the exome data and found mutations associated with adverse drug toxicities from which the patient suffered. However, PharmGKB evidence levels for many of these drug--variant combinations are currently low. In summary, our aims were to find out (a) whether gene expression or somatic mutations may explain the efficacy of bortezomib in this patient, or her bone and soft tissue metastases, which were not detected early using CT and bone scintigraphy imaging, and (b) whether certain variants may explain her adverse reactions to anthracyclines, capecitabine, and cisplatin. Finally, we also discuss hypothetical treatment options arising from the completed analysis results.

![Tumor evolution phylogeny, ancestral tumor cell and mutation-matched drug associations. The phylogenetic network shows that all three tumor nodes branch from the inferred ancestral tumor cell node mv1, which is characterized by 12 somatically mutated genes including *TP53, NOTCH3*, and *ADAM17*. The gene names on the links are the differences between a pair of nodes, harboring a rare/novel mutation predicted or known as disease-causing. Bold names indicate genes previously reported for breast cancer/TNBC. Amino acid changes are shown in Human Genome Variation Society (HGVS) nomenclature, followed by functional consequences: (U) unknown; (L) loss of function; (N) unknown but possibly neutral. A star indicates that the mutated allele was detected in the RNA-seq of the final metastasis, and two stars indicate nonsense-mediated decay of the stopgain-mutated allele. *TP53* harbors a known pathogenic mutation that is expressed. The primary tumor and first metastasis each harbor 3 additional somatically mutated genes including shared *GABRA5*, and the final metastasis shows 21 additional somatically mutated genes. Potentially favorable drugs are associated to the mutated genes with an arrow, and potentially unfavorable drugs with a "stop" arrow. Drugs that were administrated to the patient are not in parentheses; hypothetical drugs that target the known *TP53* mutation with at least some human in vivo evidence that were not administered are in parentheses. (1) Stands for hypothetical drugs that are discussed in the Discussion. The patient\'s polymorphisms in the shown germline genes are associated with adverse toxicity and lower response.](MeibnerMCS001677_F3){#MEIBNERMCS001677F3}

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

### Primary Tumor: Diagnosis and Treatment {#s2a1}

A 55-yr-old female of central European ancestry presented with breast cancer of the left mamma. [Figure 1](#MEIBNERMCS001677F1){ref-type="fig"} summarizes her patient history, course of treatments, adverse events, and associated molecular findings. She had a previous history of pollinosis and of surgeries for appendicitis, tonsillitis, a cyst at the left thyroid gland, and varicosis. Her primary tumor was a poorly differentiated invasive ductal breast carcinoma in the left lower quadrant with distinct lymphangiosis carcinomatosa. Immunohistochemical (IHC) staining of tumor tissue for the estrogen, progesterone, and Her2 receptors was negative. In a blood test, no pathogenic germline risk variants were detected in *BRCA1*, *BRCA2*, or *TP53*. Surgical treatment consisted of segmentectomy of the left mamma after sonographic marking, sentinel node biopsy, and axillary lymphonodectomy. Surgery was followed by dose escalating dose-dense sequential adjuvant chemotherapy ([@MEIBNERMCS001677C13]; [@MEIBNERMCS001677C12]) with 4× concurrent epirubicin and cyclophosphamide (EC) every 2 wk followed by paclitaxel, a microtubule-targeting agent, every 2 wk. In months 5 and 6, postoperative radiotherapy was performed on the left breast with a dose of 50.4 Gy and a boost to 61.2 Gy onto the tumor region in the lower left quadrant. Radiotherapy was furthermore applied to the ipsilateral supraclavicular and axillary lymph drainage region with a dose of 50.4 Gy.

### First Recurrence: Diagnosis and Treatment {#s2a2}

In month 17, no signs of metastases were visible using computed tomography (CT) imaging. In month 18, we diagnosed a local recurrence on the left side, a secondary tumor in the operation scar region, and another tumor at 3 o\'clock. Mastectomy was performed on the left breast and also---at the patient\'s decision---on the contralateral breast. Axillary dissection by the surgeon and histology by the pathologist showed histologically poorly differentiated invasive ductal mamma carcinoma and associated ductal carcinoma in situ (12 mm) with a high core malignancy score. Bone scintigraphy showed no signs of skeletal metastases. From months 18 to 20, three cycles of chemotherapy with cisplatin and ifosfamide were applied and then stopped because of complications (hyponatremia, genital abscess, superinfected mamma) and grade 3 adverse events (protracted nausea/emesis, hematological toxicity, polyneuropathy). From months 23 to 39, adjuvant therapy with bortezomib was applied in 14-d intervals.

### Second Recurrence: Diagnosis {#s2a3}

In month 36 the first clinical signs of local recurrence occurred. In month 39, an extensive local recurrence was diagnosed with diffuse lymphangiosis carcinomatosa and soft tissue infiltration in the left thoracic aperture, the left thoracic wall, and the shoulder girdle muscles, with infiltration into the truncus inferior of the left plexus brachialis. The patient suffered from paresis of the left shoulder. Multifocal locoregional soft tissue metastases were found prepectorally on the right side, mediastinally, along the left arteria thoracica interna, paraaortic in the abdomen, and interaortocavic immediately below the diaphragm. Bone metastases were seen in the marrow of the right proximal femur. Magnetic resonance imaging (MRI) indicated the possibility of pulmonal metastasis, and differential diagnosis came up with lymphonodular metastasis.

### Palliative Chemotherapy {#s2a4}

Palliative chemotherapy was applied using a combination of capecitabine and bevacizumab (antibody targeting VEGF) from months 39 to 43 with partial response and grade 2 and 3 hand--foot syndrome as subjectively tolerable adverse events. General system-wide and local progression occurred very suddenly in month 43, and the therapy was changed to vinorelbin monotherapy, a microtubule targeting agent. In month 46, CA15-3 increased considerably and local progression was seen, therefore the therapy was switched to gemcitabine. In month 47, rapid progression, pain, and swelling occurred. A skin metastasis biopsy was taken for IHC and next-generation sequencing analyses, and the therapy was changed to eribulin, a microtubule-targeting agent, leading to a clear response. In the course of month 48, progression occurred. Therefore, in month 49, therapy was changed to a combination of eribulin with pegylated doxorubicin, with grade 3--4 stomatitis as adverse events. Hospitalization then became necessary. Although differential diagnosis was not clear at this point, as to whether adverse events or tumor progression were the cause for the patient\'s deterioration, the doses of eribulin and pegylated doxorubicin were reduced. Pembrolizumab then was finally applied according to the patients' wish. The patient died 6 d later as a result of cancer progression at 51 mo after first diagnosis.

Genomic Analysis {#s2b}
----------------

### Next-Generation Sequencing {#s2b1}

Sequencing statistics for whole-exome sequencing (WES) and RNA sequencing of the final metastasis sample are listed in [Table 1](#MEIBNERMCS001677TB1){ref-type="table"}. For samples PB, PT, and MK, a variant call format (VCF) file was available only, hence sequencing statistics were not available to us.

###### 

Next-generation sequencing statistics for sample MF (WES and RNA-seq)

                      MF WES       RNA-seq 50 ng    RNA-seq 100 ng
  ------------------- ------------ ---------------- ----------------
  Total reads         41,389,563   110,576,133      81,360,029
  Mapped reads        99.15%       97.42%           97.64%
  Duplicated reads    39.3%        70.8%            70.8%
  On target rate^a^   77.6%        93.2%            91.7%
  Mean coverage^a^    122×         Not applicable   Not applicable

MF, final metastasis; WES, whole-exome sequencing.

^a^Mapping statistics are based on TruSeq Exome regions and computed using Qualimap without the duplicated reads.

### Somatic Signatures {#s2b2}

Mutational processes can be characterized by unique combinations of mutation types in the form of mutational signatures. We analyzed somatic mutations from the primary tumor sample and the two metastatic samples for mutational signatures based on a set of 30 signatures identified and hosted at Catalogue of Somatic Mutations in Cancer (COSMIC). We detected a total of 9/30 signatures (Signatures 1, 3, 5, 6, 7, 12, 15, 26, 29) among the three samples. Signatures 1, 3, and 12 were detected in all three samples. PT and MK shared signatures 1, 3, 7, 12, and 15, with signature 26 in addition being present in PT. Compared with PT and MK, MF did not have signatures 7, 15, and 26, but signatures 5, 6, and 29 were present ([Fig. 2](#MEIBNERMCS001677F2){ref-type="fig"}).

### Pharmacogenomic Germline Variants {#s2b3}

Relevant germline variants were detected in *CBR3, CYBA*, *CYP1B1, ERCC2, GSTP1,* and *SOD2*, which are associated with toxicity or response to anthracyclines, cyclophosphamide, and cisplatin. These variants and the evidence levels as curated by PharmGKB ([@MEIBNERMCS001677C65]) are shown in [Table 2](#MEIBNERMCS001677TB2){ref-type="table"}.

###### 

Pharmacogenomic germline variants associated with toxicity and/or effectiveness

  Gene       Genomic coordinates (hg19)   HGVS cDNA                 HGVS protein   Variant type   PharmGKB evidence level   dbSNP       Genotype   Comments
  ---------- ---------------------------- ------------------------- -------------- -------------- ------------------------- ----------- ---------- --------------------------------------------
  *CBR3*     Chr 21: 37518706             NM_001236: c.730G\>A      p.V244M        Missense       2B                        rs1056892   het        Higher doxorubicin cardiotox.
  *CBR3*     Chr 21: 37507501             NM_001236: c.11G\>A       p.C4Y          Missense       3                         rs8133052   het        Doxorub. neutropenia, cardiotox.
  *CYBA*     Chr 16: 88713236             NM_000101: c.214T\>C      p.Y72H         Missense       3                         rs4673      hom        Lower acute doxorub. cardiotox.
  *CYP1B1*   Chr 2: 38298203              NM_000104: c.1294G\>C     p.V432L        Missense       3                         rs1056836   het        Less effective dose-intense paclitaxel
  *DPYD*     Chr 1: 98348885              NM_000110: c.85C\>T       p.R29C         Missense       3                         rs1801265   hom        Decreased 5-FU tox risk
  *ERCC2*    Chr 19: 45867259             NM_001130867: c.862G\>A   p.D288N        Missense       3                         rs1799793   hom        Lower cisplatin response
  *GSTP1*    Chr 11: 67352689             NM_000852: c.313A\>G      p.I105V        Missense       2A                        rs1695      het        Increased cisplatin tox risk
  *SOD2*     Chr 6: 160113872             NM_000636: c.47T\>C       p.V16A         Missense       2B                        rs4880      het        Less effective cyclophosphamide, lower tox

PharmGKB evidence levels: 2A, moderate evidence and variant in Very Important Pharmacogene; 2B, moderate evidence; 3, unreplicated or conflicting evidence.

HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations; het, heterozygous; hom, homozygous.

### Tumor Evolution Phylogeny and Ancestral Tumor Cell Clone {#s2b4}

We constructed a phylogenetic network from somatic mutations in the primary tumor, the first metastasis, and the final metastasis, using the peripheral blood sample as the germline node in the network. The somatic mutations that we focused on are shown in [Figure 3](#MEIBNERMCS001677F3){ref-type="fig"}. No homozygous mutation was seen among these somatic mutations. All included somatic mutations were either unknown or occur with a low allele frequency in the general population. Six of these mutations are known to occur in cancer patients (i.e., the *TP53, HCFC1, ADD3, IL17RD, PIK3C2G, ROCK1* mutations) and all remaining mutations were predicted to be damaging by two prediction tools, MutationTaster ([@MEIBNERMCS001677C49]) and Combined Annotation-Dependent Depletion (CADD) ([@MEIBNERMCS001677C28]). The network shows that all three tumor samples evolved from a common precursor tumor clone with 12 somatic mutations shared in all three tumor samples ([Fig. 3](#MEIBNERMCS001677F3){ref-type="fig"}). Of note, this precursor clone includes somatic missense mutations in *TP53*, *HCFC1*, *ADAM17*, and *ITPR2*, which are detailed in [Table 3](#MEIBNERMCS001677TB3){ref-type="table"}. The primary tumor additionally includes missense mutations in *GABRA* (shared with the first metastasis, [Table 3](#MEIBNERMCS001677TB3){ref-type="table"}), *CHAD*, and others ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}). The first metastasis (month 18) includes missense mutations in *DKGZ* and *ADD3* ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}), and the final metastasis (month 47) harbors 18 additional missense mutations and also three stopgain mutations, in *FXR1*, *PCDHGB4*, and *ROCK1* ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}).

###### 

Somatic rare pathogenic or predicted damaging mutations, which are discussed in the Results or Discussion

  Gene                                                         Genomic coordinates (hg19)   HGVS cDNA                  HGVS protein   Variant type   Predicted effect   dbSNP, COSMIC           Genotype   Comments
  ------------------------------------------------------------ ---------------------------- -------------------------- -------------- -------------- ------------------ ----------------------- ---------- -----------------------------------------------------------------------
  **Shared mutations in all tumor samples**                                                                                                                                                                
  *ADAM17*                                                     Chr 2: 9633900               NM_003183: c.1969G\>A      p.D657N        Missense       D/34                                       het        RNA. TNBC, BrCa progression
  *CCDC14*                                                     Chr 3: 123680145             NM_022757: c.20G\>C        p.R7P          Missense       D/16                                       het        RNA. Centriole duplication
  *HCFC1*                                                      Chr X: 153224834             NM_005334: c.1553C\>T      p.S518F        Missense       D/25                                       het        RNA. BrCa driver, *BRCA1* pathway
  *ITPR2*                                                      Chr 12: 26835564             NM_002223: c.1191G\>T      p.W397C        Missense       D/21                                       het        RNA. BrCa
  *NFRKB*                                                      Chr 11: 129758492            NM_006165: c.373C\>G       p.R125G        Missense       D/17                                       het        RNA. Candidate oncogene
  *NOTCH3*                                                     Chr 19: 15272207             NM_000435: c.6232C\>T      p.R2078W       Missense       D/17                                       het        Neural development, BrCa
  *RTN4*                                                       Chr 2: 55254481              NM_020532: c.754C\>G       p.L252V        Missense       D/15                                       het        Cell adhesion, migration, metastasis, and apoptosis
  *SYBU*                                                       Chr 8: 110588198             NM_001099746: c.572G\>C    p.R191P        Missense       D/21                                       het        RNA. Microtubule and neural associated
  *THRAP3*                                                     Chr 1: 36748223              NM_005119: c.59C\>T        p.S20L         Missense       D/28                                       het        RNA. Cancer growth, damage response
  *TP53*                                                       Chr 17: 7578190              NM_000546: c.659A\>G       p.Y220C        Missense       D/22               rs121912666 COSM10758   het        RNA. Pathogenic. Germline in Li--Fraumeni, somatic
  *TRPM6*                                                      Chr 9: 77390891              NM_001177310: c.3296C\>T   p.P1099L       Missense       D/21                                       het        BrCa, magnesium homeostasis
  *ZNF384*                                                     Chr 12: 6781631              NM_001135734: c.979G\>A    p.A327T        Missense       D/21                                       het        RNA. Fusions with *TAF15* or *EP300* in ALL
  **Shared mutations in primary tumor and first metastasis**                                                                                                                                               
  *GABRA5*                                                     Chr 15: 27185116             NM_000810: c.769A\>T       p.I257F        Missense       D/23                                       het        GABA inhibits BrCa cell migration
  **Private mutations in primary tumor**                                                                                                                                                                   
  *TCF3*                                                       Chr 19: 1619388              NM_001136139: c.1253T\>C   p.L418P        Missense       D/17                                       het        Not a mutational driver in BrCa
  *XXYLT1*                                                     Chr 3: 194991727             NM_152531: c.61C\>T        p.R21C         Missense       D/24                                       het        NOTCH pathway
  **Private mutations in first metastasis**                                                                                                                                                                
  *ADD3*                                                       Chr 10: 111890220            NM_001121: c.1708G\>A      p.E570K        Missense       D/33               COSM914716              het        Endometrial carcinoma
  *DGKZ*                                                       Chr 11: 46354955             NM_201532: c.130G\>T       p.E44X         Stopgain       D/37                                       het        Induces cell-cycle arrest, is target of p53
  **Private mutations in final metastasis**                                                                                                                                                                
  *FXR1*                                                       Chr 3: 180688068             NM_001013438: c.1525C\>T   p.R509X        Stopgain       A/36                                       het        RNA. Activation of cyclin-dependent kinase inhibitors, p53
  *HMGCR*                                                      Chr 5: 74655244              NM_001130996: c.2161A\>T   p.S721C        Missense       D/24                                       het        RNA. BrCa, dereg. lipogenesis ass. with mut. p53
  *IL17RD*                                                     Chr 3: 57132008              NM_017563: c.1723C\>T      p.R575W        Missense       D/16               COSM249014              het        RNA. BrCa. epithelial to mesenchymal transformation, migration/invas.
  *IQGAP1*                                                     Chr 15: 90999512             NM_003870: c.1741G\>A      p.D581N        Missense       D/20                                       het        RNA. BrCa. Cell invasiveness
  *PCDHGB4*                                                    Chr 5: 140767815             NM_003736: c.364G\>T       p.E122X        Stopgain       A/34                                       het        Nonsense-mediated decay. BrCa.
  *PIK3C2G*                                                    Chr 12: 18552594             NM_004570: c.2005C\>T      p.L669F        Missense       D/19               rs61754413              het        Gene implicated in cancer development
  *ROCK1*                                                      Chr 18: 18535139             NM_005406: c.3580A\>T      p.K1194X       Stopgain       A/50                                       het        RNA. Malignant ascites in gastric cancer
  *SLC15A1*                                                    Chr 13: 99339879             NM_005073: c.1783G\>A      p.E595K        Missense       D/35                                       het        RNA. Overexpressed in some cancers. Substrate transport.

HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations; COSMIC, Catalogue of Somatic Mutations in Cancer; RNA, somatic mutation also detected in RNA-seq of final metastasis; TNBC, gene associated with triple-negative breast cancer; BrCa, gene associated with breast cancer; ALL, gene associated with acute lymphoblastic leukemia; het, heterozygous; hom, homozygous. Predicted effect from MutationTaster is disease-causing (D) or disease-causing-automatic (A), and from Combined Annotation-Dependent Depletion (CADD) is the Phred-like C score.

### Recurrent Somatic Nonsynonymous Mutations in All Three Tumor Tissue Samples {#s2b5}

The somatic *TP53* mutation p.Y220C (or p.Y61C, p.Y88C, or p.Y181C, depending on transcript variant; Database for Short Genetic Variations \[dbSNP\] ID rs121912666) ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}), was heterozygous in each tumor sample, with an allele frequency of ∼0.5 (between 0.36 and 0.58). It is a known somatic mutation in COSMIC in at least 37 breast cancer tissue samples (at time of writing), and also in ovary, esophagus, upper aerodigestive tract, and lung cancers. In ClinVar, the mutation has not previously been reported as a somatic tumor tissue mutation but has been reported as a pathogenic germline Li--Fraumeni syndrome variant. The mutation p.Y220C is localized in the core domain of p53 and by introducing a surface crevice it leads to accelerated denaturing of the protein at body temperature ([@MEIBNERMCS001677C5]). The *HCFC1* p.S518F mutation has been reported in a melanoma patient ([@MEIBNERMCS001677C23]) (patient 13). The remaining recurrent somatic mutations in all three tumor samples are not yet reported, to our knowledge. For *SYBU* the G\>A and G\>T mutations have been reported in COSMIC but not the patient\'s c.572G\>C mutation. All somatic mutations were clearly detected in the RNA-seq data of the final metastasis, except for *NOTCH3, TRPM6,* and *RTN4,* with only one mutated RNA read each. For *NOTCH3* and *TRPM6*, the wild-type expression was halved compared with the in-house healthy controls.

### Recurrent Somatic Nonsynonymous Mutation in Primary Tumor and First Metastasis {#s2b6}

The *GABRA5* mutation ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}) has not been reported to our knowledge and its functional consequences are unknown.

### Private Somatic Nonsynonymous Mutations in Primary Tumor {#s2b7}

The mutations in *TCF3* and *XXYLT1* ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}) are novel to our knowledge.

### Private Somatic Nonsynonymous Mutations in First Metastasis {#s2b8}

The stop mutation *DGKZ* p.E44\* ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}) is novel to our knowledge. The missense mutation *ADD3* p.E570K is reported in COSMIC to be seen in three The Cancer Genome Atlas (TCGA) endometrial carcinoma samples (<http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=914716>). *ADD3* p.E570K is predicted as tolerated by Alamut Visual (AlignGVD class C0, SIFT tolerated) but as disease-causing by MutationTaster and CADD.

### Private Somatic Nonsynonymous Mutations in Final Metastasis {#s2b9}

Of the 21 private mutations, all three stopgain mutations (*ROCK1* p.K1194\*, *FXR1* p.R509\*, *PCDHGB4* p.E122\*) are expressed on the RNA level and are predicted to be the most damaging ([Table 3](#MEIBNERMCS001677TB3){ref-type="table"}). The *ROCK1* p.K1194\* mutation lies in the first exon, knocking out all protein-binding regions of this allele, and has been reported in a lung cancer cell line ([@MEIBNERMCS001677C55]). The *PCDHGB4* p.E122\* mutation also lies in the first exon, within the cadherin protein domain. The mutation in *FXR1* lies in exon 16 near the protein-binding region. Thirteen of the 18 private missense mutations were found expressed on the RNA level: *ADRBK2, AGAP1, CEBPZ, CNTN3, DBNL, FBP2, HMGCR, IL17RD, IQGAP1, KLHL28, METTL4, SLC15A1,* and *WDR37* ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)). *IL17RD* p.R575W has been reported as a somatic mutation in pancreatic cancer ([@MEIBNERMCS001677C67]). The *SLC15A1* (aka *HPEPT1*) p.E595K mutation has been reported as a loss-of-function mutation ([@MEIBNERMCS001677C68]). The following genes or their somatically mutated alleles were not detected as expressed: *CPXM2, DUSP26, KCNG2, LPPR4, PIK3C2G,* and *PCDHGB4*. *CPXM2* p.G50R was imputed as a germline variant for a noncancer patient (A Kainz, pers. comm.).

Differential Gene Expression {#s2c}
----------------------------

We analyzed differential gene expression by comparing the patient\'s expression data (two replicates) from the final metastasis sample against a set of 11 normal breast tissue controls. Of note, 9810/19,301 genes (51%) were significantly differentially expressed between the patient\'s tumor samples and the controls ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)). A total of 4591 genes were up-regulated and 5219 genes were down-regulated. Of these genes, 4851 had a greater than twofold (log~2~) and 1536 a greater than fourfold (log~2~) difference in expression level. The 10 most up- and down-regulated genes are presented in [Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1). Among the differentially expressed genes, 410 could be assigned as "breast cancer--relevant" based on a list of 433 breast cancer--relevant genes generated using GLAD4U webservice. The 10 most up- and down-regulated breast cancer relevant genes as defined by this method are presented in [Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1). KEGG Pathway enrichment analysis on the differentially expressed, breast cancer--relevant genes revealed 31 KEGG pathways showing significant enrichment with those genes ([Supplemental Table 5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)).

Drug--Gene Interaction {#s2d}
----------------------

Querying the Drug--Gene Interaction Database (DGIdb; <http://dgidb.genome.wustl.edu/>) ([@MEIBNERMCS001677C21]) for drug--gene interactions using differential up-regulated genes (log~2~ FC \> 1) revealed a candidate list of 60 compounds across 16 genes ([Table 4](#MEIBNERMCS001677TB4){ref-type="table"}). With respect to the applied anthracyclines (epirubicin, doxorubicin), microtubule inhibitors (paclitaxel, vinorelbine, and eribulin), and bortezomib: *TOP2A*, members of the microtubule gene family, and members of the proteasome gene family and were up-regulated 29-fold, 3.6-fold, and 5.6-fold, respectively ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)).

###### 

Overexpressed breast cancer relevant genes associated with clinical compounds

  Symbol     Entrez   Log~2~FC   Clinically actionable compound(s)
  ---------- -------- ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  *RAD51*    5888     5          Amuvatinib
  *TOP2A*    7153     4.9        **Daunorubicin**, **Doxorubicin**, **Epirubicin**, **Idarubicin**, **Dexrazoxane**, Lucanthone, **Amsacrine**, **Mitoxantrone**, **Teniposide**
  *AURKB*    9212     4.5        Danusertib, Tozasertib, AT9283, GSK1070916, PF-03814735, Barasertib, SNS-314, ML8237
  *AURKA*    6790     4.3        PF-03814735, Alisertib, SNS-314, AT9283, ENMD-2076, Danusertib, Tozasertib, ML8237
  *CHEK1*    1111     3.6        Rabusertib, SCH900776, AZD7762
  *CHEK2*    11200    2.0        AZD7762
  *NOTCH1*   4851     2.0        RO4929097, γ-Secretase
  *PARP1*    142      1.9        Veliparib, **Olaparib**, **Rucaparib**
  *PIK3R2*   5296     1.9        Apitolisib, Pilaralisib, GSK2636771, Pictilisib, PI-103, Gedatolisib, SF1126, Sophoretin, Omipalisib
  *RRM1*     6240     1.8        **Fludarabine**, **Gemcitabine**, **Hydroxyurea**, **Cladribine**
  *SYK*      6850     1.7        Fostamatinib
  *CDK4*     1019     1.6        **Palbociclib**, Abemaciclib, Ribociclib, Alvocidib
  *AKT1*     207      1.5        MK2206, Ipatasertib, Perifosine, AZD5363
  *MAP2K1*   5604     1.4        TAK-733, RO4987655, Pimasertib, Refametinib, AZD8330, **Trametinib**, Selumetinib, GDC-0623, **Cobimetinib**
  *ALK*      238      1.3        **Brigatinib**, **Crizotinib**, Ganetespib, Ensartinib, ASP3026
  *ERBB3*    2065     1.1        AV-203, GE-huMab-HER3, Patritumab, Seribantumab, LMJ716, REGN1400, H4B-121Ab, MM-111, Duligotuzumab, Istiratumab, GSK2849330, KTN3379, **Osimertinib**

Sources: MyCancerGenomeClinicalTrial, TALC, DrugBank, MyCancerGenome, CancerCommons (aggregated by DGIdb)---initial results returned from DGIdb have been manually revised and curated.

Bold indicates Federal Drug Administration (FDA)-approved drugs (on-label as well as off-label); all other drugs are preclinical or in clinical trials. Names ending in ib (small molecule inhibitor) or ab (antibody) indicate gene (or mutation) specificity.

Log~2~FC, log~2~ of fold change.

Immunohistochemical Staining {#s2e}
----------------------------

To validate the RNA-seq overexpression findings for sample MF in the absence of matched normal tissue from the same patient, we used antibody staining on the same tissue sample. We used antibodies that were available and properly established in our pathology laboratories. [Figure 4](#MEIBNERMCS001677F4){ref-type="fig"} shows that *CDK4* transcript up-regulation (threefold) and *MKI67* up-regulation (13-fold) is clearly validated by IHC. ALK staining was negative, although RNA-seq analysis revealed a 2.4-fold up-regulation of transcript levels. Androgen receptor staining was weakly positive in 20% of lesional cells although RNA-seq indicated strong down-regulation in the patient\'s metastasis sample compared with the control samples.

![CDK4-immunohistochemical staining of final skin metastasis. Histopathological findings. (*A*) Islands of tumor cells are identified within the dermis (hematoxylin and eosin, 100×). (*B*) High Ki-67 proliferation index marks the nuclei of many neoplastic cells. This independently validates the 13-fold RNA-seq overexpression that was averaged over the final metastasis tissue sample (400×). (*C*) Tumor cell nuclei stain weakly but distinctly for CDK4, independently validating the threefold averaged RNA-seq overexpression (400×). (*D*) Isotype negative control with no detectable staining (400×).](MeibnerMCS001677_F4){#MEIBNERMCS001677F4}

DISCUSSION {#s3}
==========

In this case study, we aimed to identify potential targeted drugs using an exome- and transcriptome-based molecular profile of the patient\'s tumor and metastases. We also examined whether the molecular profile may explain the response or nonresponse to the administered drugs, the adverse events to some of the drugs, and the high aggressiveness seen in this individual TNBC case. To rapidly inform of potential targeted drugs, we scanned the existing whole-exome results for novel and known drug-associated somatic tumor tissue mutations in only those genes that are listed in <https://www.mycancergenome.org/> and some commercial cancer panels, as well as in *TP53, BRCA1, BRCA2*. This first scan only found a single mutation---that is, the heterozygous damaging somatic mutation in *TP53* in both tumor samples but not the germline sample. Our later in-depth analyses confirmed the *TP53* mutation to be drug- and disease-relevant in the context of the complete set of somatic mutations in the tumor samples. To inform of potential further targeted treatments ([Table 4](#MEIBNERMCS001677TB4){ref-type="table"}), we also sequenced the whole transcriptome from the final metastasis sample, scanned for overexpressed genes by comparing the patient\'s sample with a set of healthy breast tissue controls, and validated the overexpressed genes on the protein level using available antibody stains. Metastatic tumor nodes accumulate a significant number of mutations that should be considered for treatment and that were not present in the primary tumor. For this reason, we analyzed the complete whole-exome data of the primary tumor and the two metastatic samples, classified each tumor sample using the COSMIC somatic signatures, and performed extensive database and literature research for the identified somatic tumor tissue mutations that were predicted as damaging. Because more than one tumor sample was available, we were able to see the shared mutations in each tumor sample that could be addressed with the same treatment, which serves to narrow down the lengthy list of potential treatments.

Somatic Signatures {#s3a}
------------------

Somatic signatures from the Sanger Center\'s COSMIC website (<http://cancer.sanger.ac.uk/cosmic/signatures>) allow a quick classification based on lists of somatic tumor tissue mutations that may otherwise be difficult to interpret, and may provide a first answer for patients who ask how and why their tumor started. [Figure 2](#MEIBNERMCS001677F2){ref-type="fig"} shows that the earlier tumors PT and MK are associated with aging and ultraviolet light exposure (∼25%--30% Signature 1 and ∼10% Signature 7) and failure of DNA damage repair (∼20%--25% Signature 3---*BRCA1/2*-related, and ∼15%--25% Signature 15). For PT, there is also ∼10% Signature 26, which is associated with defective DNA mismatch repair. The causes of Signature 12 (∼10%--20%) are unknown, probably because it is usually seen in liver metastases, which may arise from a wide range of primary tumors. For MF the main signature is DNA damage repair failure (∼40% Signature 3 and ∼15% Signature 6), aging (∼10% Signature 1), and relatively uninformative remaining signature contributions (∼10% unknown, ∼10% Signature 29---gingivo-buccal oral squamous cell carcinoma, ∼10% Signature 12---liver cancer, ∼10% Signature 5---found in most cancers with unknown etiology).

Tumor Evolution Phylogeny {#s3b}
-------------------------

The concept of applying phylogenetic methods to analyze tumor evolution is not new ([@MEIBNERMCS001677C53]; [@MEIBNERMCS001677C37]). Having established the tumor evolution phylogeny, it is tempting to estimate the timespan for the ancestral tumor cell to evolve into the primary tumor. This may give an indication of the time window for early detection of the expanding tumor cell population. A stringent estimation method including error bounds is given in [@MEIBNERMCS001677C48], which assumes a star-like phylogeny and a linear mutation rate. In cancer cells, the mutation rate depends on the number of mutations and the genes that are mutated ([@MEIBNERMCS001677C31]). Our patient\'s tumor evolution phylogeny is nearly star-like, but with only three tumor samples it is too sparse for applying the stringent estimation method. Therefore, we compared the discovery times and branch lengths of the final metastasis and the primary tumor with each other, and taking the mutation rate to be identical for both branches, we estimated that there was a time window of possibly only 6 mo for earlier detection of the primary tumor in our patient.

Somatic Mutations in the Inferred Ancestral Tumor Cell and Detected in All Three Tumor Samples {#s3c}
----------------------------------------------------------------------------------------------

### TP53 p.Y220C {#s3c1}

The heterozygous pathogenic somatic tumor tissue mutation rs121912666 in *TP53* is probably not the single driver mutation, because it is reported in ClinVar as a pathogenic germline variant for Li--Fraumeni cases, meaning that affected patients can live disease free for years or decades. The 12 predicted damaging somatic tumor tissue mutations in the trunk of our phylogenetic tumor evolution tree ([Fig. 3](#MEIBNERMCS001677F3){ref-type="fig"}) also strongly suggest that the viable ancestral tumor cell required multiple damaging mutations that may include several or all of these 12 mutations or the nine mutations detected to be highly expressed in the RNA-seq. However, p53 is a key apoptosis protein. On the functional level, this specific p.Y220C mutation does not affect the binding regions but leads to protein destabilization and much more rapid denaturing than wild-type p53 ([@MEIBNERMCS001677C5]). On the frequency level, the p.Y220C mutation is reported as the ninth most frequent p53 mutation, affecting approximately 75,000 new cancer patients worldwide every year ([@MEIBNERMCS001677C5]). Specifically, the p.Y220C mutation (aka p.Y88C) has been reported as a heterozygous somatic driver mutation in a Chinese breast cancer patient ([@MEIBNERMCS001677C54]). In our patient, the mutated *TP53* allele was expressed in 90% of all transcripts in the final metastasis that we biopsied. The p53-mediated apoptosis pathway may therefore have been impaired significantly in her tumor cells.

It can hence be argued that the success of 11 mo of progression-free survival under bortezomib (proteasome inhibitor) experimental treatment was due to p53-independent apoptosis. Bortezomib was selected by the treating clinician as off-label therapy because of a published role of proteasome inhibitors in TNBC as determined by short interfering RNA (siRNA) screens ([@MEIBNERMCS001677C41]). The course of disease suggests but does not prove transient therapeutic activity. Bortezomib has previously been reported to up-regulate *CASP3*, *CASP8*, and *CASP9* ([@MEIBNERMCS001677C47]), and down-regulate *BCL2* ([@MEIBNERMCS001677C20]). Significant up-regulation of some proteasome transcripts underlined this possible activity of bortezomib in the TNBC patient. The *TP53* mutation also suggested use of *BCL2* inhibition (venetoclax); however, the RNA-seq data were inconclusive because of low coverage in *BCL2*. Impaired p53 has been associated with doxorubicin resistance ([@MEIBNERMCS001677C17]). To overcome the resistance, an in vitro experiment successfully combined doxorubicin with a PARP inhibitor ([@MEIBNERMCS001677C36]). APR-246 (aka PRIMA-1), the first drug in clinical trials that directly targets mutant p53 is currently in a Phase 1b/II clinical trial (PiSSARO, ClinicalTrials.gov ID NCT02098343). APR-246 showed strong synergies with cisplatin in p.Y220C-mutated cancer cell lines ([@MEIBNERMCS001677C35]), and also with olaparib in p53-mutated non-small-cell lung cancer cell lines ([@MEIBNERMCS001677C16]). Further compounds such as PK7088 that specifically target the p.Y220C induced crevice are in preclinical development ([@MEIBNERMCS001677C25]; [@MEIBNERMCS001677C30]).

### ADAM17 p.D657N and NOTCH3 p.R2078W {#s3c2}

The enzyme encoded by *ADAM17,* also known as tumor necrosis factor-α-converting enzyme (TACE) sheds the extracellular domain of various receptors such as heparin-binding EGF, transforming growth factor-α (TGFA), amphiregulin (AREG), neuregulin (NRG), epiregulin (EREG), and β-cellulin (BTC) ([@MEIBNERMCS001677C34]) from the cell membrane leading to an activation of downstream signaling pathways with significance in triple-negative breast cancer cells ([@MEIBNERMCS001677C7]). *NOTCH3* is a reported breast cancer driver gene where inactivating mutations or deletions in the PEST domain activate the Notch pathway ([@MEIBNERMCS001677C63]). For breast cancer, the known somatic mutations form a cluster in the PEST region of our patient\'s p.R2078G mutation (<https://www.intogen.org/search?gene=NOTCH3&cancer=BRCA>). *NOTCH3* expression was nearly undetectable in our RNA-seq data of the tumor tissue. At the Avera Cancer Institute, we see *ADAM17* and Notch aberrations quite often in TNBC (B Leyland-Jones, pers. comm.). γ-Secretase inhibitors are under development for this pathway ([@MEIBNERMCS001677C38]; [@MEIBNERMCS001677C63]).

### The Remaining Shared Somatic Mutations and Their Potential Co-Driver Roles {#s3c3}

The *HCFC1* gene is reported as a major downstream effector of *BRCA1*-associated protein 1 ([@MEIBNERMCS001677C26]) and as a breast cancer driver gene ([@MEIBNERMCS001677C9]). The *HCFC1* mutation ties in with somatic signature 3, which is reported for *BRCA1-* or *BRCA2-*associated failure of DNA double-strand break repair. *ITPR2* is associated with estradiol-induced breast cancer; ITPR2 inhibitors include caffeine and the experimental compounds 2-APB and xestospongin C (XeC) ([@MEIBNERMCS001677C59]). NFRKB modulates NFKB1 and is being evaluated as a candidate oncogene ([@MEIBNERMCS001677C6]). *THRAP3* has been associated with prostate cancer growth ([@MEIBNERMCS001677C24]) and DNA damage response ([@MEIBNERMCS001677C3]). *ZNF384* fusions with *TAF15* or *EP300* are associated with acute lymphoblastic leukemia ([@MEIBNERMCS001677C42]; [@MEIBNERMCS001677C27]). Together, these seven genes and their expressed mutated alleles appear to be a plausible driver mutation combination required for a viable ancestral tumor cell. The *SYBU* mutation also appears to be relevant because its expression is detected in MF, despite being so far known only to be expressed in nerve cells. *SYBU* encodes syntabulin, which is a microtubule-associated protein that mediates transport of vesicles to neuronal processes ([@MEIBNERMCS001677C58]; [@MEIBNERMCS001677C70]). *TRPM6* is involved in magnesium homeostasis and epithelial magnesium transport, and somatic mutations clustering in the same region have been reported in Chinese breast cancer patients ([@MEIBNERMCS001677C71]). The role of magnesium in cancer development is much debated ([@MEIBNERMCS001677C61]), and it seems to vary depending on stage such as carcinogenesis, primary tumor growth, and metastasis formation (V Trapani, pers. comm.). *RTN4* is associated with cell adhesion, migration, metastasis, and apoptosis in various cancers ([@MEIBNERMCS001677C10]; [@MEIBNERMCS001677C69]). Mutated alleles of *TRPM6* and *RTN4* were nearly undetectable in our RNA-seq data of the tumor tissue.

Perhaps Actionable Somatic Nonsynonymous Mutations That Do Not Appear in All Three Tumor Samples {#s3d}
------------------------------------------------------------------------------------------------

We identified 26 mutations that were predicted damaging and that were not shared in all three tumor samples. The therapeutical and functional consequences of these mutations are currently not known, therefore any inferences are speculative. However, it is striking that nearly all of the mutated genes are known to be associated with TNBC, breast cancer, other cancers, invasion, metastasis, proliferation, relapse, and so on. A full discussion of all 26 genes is beyond the scope of this section, but interested readers can refer to the [Supplemental Material](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1) for a short comment on the relevance of each gene. We now briefly discuss potential targets found to be mutated in the patient, for which inexpensive repurposed drugs and an expensive leukemia treatment could be considered.

### Primary Tumor and First Metastasis {#s3d1}

Regarding mutated *GABRA5* in the primary tumor (PT) and the first metastasis (MK), the wild-type gene encodes a receptor for its ligand GABA, which inhibits norepinephrine-induced migration of breast and colon carcinoma cells ([@MEIBNERMCS001677C18]). Lorazepam, an approved GABA agonist often used to treat anxiety disorders in cancer patients, may have a potential use as an anti-metastatic drug ([@MEIBNERMCS001677C18]). The nonspecific β-blocker propranolol inhibits norepinephrine-induced migration of breast cancer cells and increases the cytotoxicity of natural killer cells, reducing distant metastases and improving 10-yr survival significantly from 70% to 90% ([@MEIBNERMCS001677C43]). In nonrandomized comparisons of treated versus untreated ovarian cancer cohorts---characterized by mutated p53 in most patients---propranolol cohorts showed increased median overall survival ([@MEIBNERMCS001677C64]).

### Primary Tumor {#s3d2}

Regarding mutated *TCF3* in the primary tumor, the wild-type gene encodes a key transcription factor for lymphopoiesis ([@MEIBNERMCS001677C19]), and a successful therapy protocol exists for the *TCF3-PBX1* acute lymphoblastic leukemia subtype.

### Final Metastasis {#s3d3}

Regarding the mutated genes *HMGCR* and *IQGAP1* in the final metastasis (MF): *HMGCR* encodes the rate-limiting enzyme in the mevalonite pathway. Pharmacologic inhibition of *HMGCR* with statins is reported to inhibit breast cancer cell growth in vitro ([@MEIBNERMCS001677C40]), reduce the risk and/or severity of breast cancer ([@MEIBNERMCS001677C14]), exhibit antimetastatic and antitumorigenic effects in ovarian cancer ([@MEIBNERMCS001677C57]), and show anticancer effects in gastric cells ([@MEIBNERMCS001677C11]). *IQGAP1* was associated with breast cancer cell invasion ([@MEIBNERMCS001677C2]), and its protein was reported as one of two binding targets of disulfuram (an anti--alcohol addiction drug), as a suggested TNBC combination treatment with doxorubicin ([@MEIBNERMCS001677C2]).

Whole-Transcriptome Sequencing {#s3e}
------------------------------

Whole-transcriptome sequencing of tumor RNA is of immense value to inform of overexpressed target genes and fusions in addition to the targets that can be identified by DNA-based mutation analysis alone. Furthermore, the functional effect of a tumor mutation can sometimes be tracked by looking at the expression of genes downstream from the mutated gene. For example, a *FLT3* mutation of "unknown significance" in combination with overexpression of the downstream RNA transcripts for *RAS*, *RAF*, and *MEK* would be hypothesized as an activating *FLT3* mutation; therapeutic consequences would be consideration of FLT3 inhibitors quizartinib or sorafinib, or downstream MEK inhibitors trametinib or cobimetinib. (The *FLT3* mutation was a low-confidence mutation in this case study, which turned out to be an artefact.) Lastly, mutations that are not seen in RNA may be of secondary interest as probably being passenger mutations, whereas mutations detected in DNA can be considered validated if also seen in RNA.

In this case study we compared the RNA-seq data from the final metastasis sample against in-house healthy controls to obtain gene expression profiles. We saw an up-regulation of breast cancer relevant genes, many of which have been reported to be associated with proliferation, tumor progression, poor prognosis, or resistance to therapy. A small selection will be discussed here, and the interested reader is referred to [Supplemental Data](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1) for a discussion of further genes. The significance of the *TP53* mutation that was detected in the exomes ties in with the expression-based gene set enrichment analysis that ranks the p53 signaling pathway on rank 2 ([Supplemental Table 5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)). On the single-gene level, overexpression of survivin (*BIRC5*) supports the anti-apoptosis theme. Survivin overexpression has been shown to inhibit apoptosis, promote mitosis, and to facilitate angiogenesis ([@MEIBNERMCS001677C32]). It has further been linked to drug/radiation resistance ([@MEIBNERMCS001677C32]) as well as being associated with poor prognosis ([@MEIBNERMCS001677C60]; [@MEIBNERMCS001677C56]). Survivin has been established as a specific cancer cell target for preclinical immunotherapeutics ([@MEIBNERMCS001677C4]). Overexpression of homeodomain transcription factor *HOXB13* has been shown to correlate with tamoxifen resistance in ER-positive breast cancer ([@MEIBNERMCS001677C52]). *HOXB13* is used as a biomarker within the breast cancer index (BCI) ([@MEIBNERMCS001677C51]; [@MEIBNERMCS001677C50]). Cyclin E1 (*CCNE1*) is a well characterized oncogene. Overexpression in breast cancer is associated with proliferation and poor prognosis ([@MEIBNERMCS001677C8]). At the Avera Cancer Institute, we frequently observe aberrations in *CCNE1* in TNBC and ovarian tumors (B Leyland-Jones, pers. comm.). CDK2 inhibitors are in clinical trials to target *CCNE1* amplification. *CCNE1* overexpression is in agreement with the highly significant cell-cycle pathway that the gene set enrichment analysis placed on rank 3 ([Supplemental Table 5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)). The *RAD51* overexpression ties in with the highly significant homologous recombination pathway in the gene set enrichment analysis (rank 6) and with the Somatic Signature 3 ([Fig. 1](#MEIBNERMCS001677F1){ref-type="fig"}, Homologous recombination failure in breast and other cancers). At the Avera Cancer Institute, we would consider a poly ADP ribose polymerase (PARP) inhibitor or a platinum-based therapy. *RAD51* overexpression was also reported to increase during breast cancer progression and metastasis and to promote the development of distant metastasis in TNBC ([@MEIBNERMCS001677C66]).

Down-regulation of the progesterone receptor (*PGR*) ([@MEIBNERMCS001677C44]) and of *GSTM1* (S Willis, unpubl.) are prognostically bad ([Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)). Topoisomerase II α (*TOP2A*) overexpression, independent from amplification, is highly associated with cell proliferation and aggressive tumor subtypes ([@MEIBNERMCS001677C46]). *TOP2A* was up-regulated 29-fold, providing an expression-based rationale for therapeutic attempts with epirubicin and doxorubicin, but in the patient\'s case neither drug worked and she suffered from grade 3--4 stomatitis. The tubulin β chain (*TUBB*) expression was up-regulated 3.3-fold. The patient received paclitaxel, vinorelbin, and eribulin, which target tubulin β chain according to DrugBank ([www.drugbank.ca](www.drugbank.ca)). Although paclitaxel was applied within the Citron protocol, and vinorelbin and eribulin appeared to halt progression temporarily, their efficacy was disappointing compared with a Belgian trial ([@MEIBNERMCS001677C1]) and not obvious compared with bortezomib. *PSMB5* and *PSMB1* were up-regulated 5.6-fold and threefold, respectively. These members of the proteasome gene family are inhibited by bortezomib ([www.drugbank.ca](www.drugbank.ca)), showing that not necessarily the highest up-regulated genes need be prioritized for a relatively long period of progression-free survival. A typical combination therapy to enhance the response to bortezomib in multiple myeloma is to add dexamethasone or to combine bortezomib, dexamethasone, and the histone deacetylase (HDAC) inhibitor panobinostat (which would have addressed the up to sevenfold up-regulated HDAC gene family members).

Hypothetical Surveillance of Treatment Response Using cfDNA Panels {#s3f}
------------------------------------------------------------------

In the terminal stage, the standard blood biomarker CA15-3 was stable, but skin metastases showed a completely different picture of rapid disease progression. The longitudinal detection at different treatment time points of somatic mutations in cell-free DNA (cfDNA) from blood plasma was first introduced on a large scale in the United States in 2014. In Germany, these longitudinal tests are not reimbursed by the public health insurers and are little known. The surveillance of the *TP53* mutation, which would have been detected by any current cfDNA gene panel, possibly could have been more accurate than CA15-3 ([@MEIBNERMCS001677C15]; [@MEIBNERMCS001677C22]; [@MEIBNERMCS001677C39]). To gain information on actionable mutations, a broad cfDNA panel is needed. cfDNA next-generation sequencing (NGS) tests may pay for themselves by guiding drug choice and saving costs by detecting the lack of drug response at an early stage of treatment.

Conclusion {#s3g}
----------

This was a first pilot for our ongoing multicenter collaboration to synergize our efforts and investigate methods to improve patient testing and the selection of therapies. This case study demonstrates that molecular profiling, if performed fast and early in the course of disease, can inform on potential targets and drugs, with the proviso that it alone cannot always reliably predict whether a drug will work: specifically, the patient\'s very high *TOP2A* expression level was an unsuitable biomarker for the selection of the anthracyclines that the patient received. Likewise, the *RRM2* and *TYMS* overexpression do not appear suitable biomarkers for the indication of gemcitabine. However, the moderate *TUBB* overexpression tied in with the moderate and short-lived successes of vinorelbin and eribulin. The *TYMS* overexpression tied in with the moderate capecitabine response. The molecular case for possible bortezomib activity was plausible on the *TP53* mutation level and the proteasome overexpression level. However, facing the multitude of genetic information and their potential link to pharmacologically actionable target patterns, from a clinical perspective it will be a major task to build relevance-based algorithms for interventions. Furthermore, every NGS-guided choice of targeted drugs has to be prospectively compared with clinical choice of therapy regimen delineated from several generations of controlled trials to place them correctly into our therapeutic armamentarium. In view of the tremendous amount of information that can be extracted from NGS and needs to be researched, validated, and summarized, timely whole-exome and transcriptome diagnostics should be considered at an early point in time, when the first line of treatment begins and when healthy reference tissue is still available. We suggest that mutated *TP53* does not need to be seen as unrelated to treatments or as a desolate prognosis, but that many p53-independent treatments already exist that may be considered.

METHODS {#s4}
=======

DNA library preparation and exome capture were executed using the Kapa Hyper Plus Library Prep Kit and the SeqCap EZ MedExome Target Enrichment Kit (Roche). Paired-end whole-exome sequencing was performed on the Illumina NextSeq 500 platform, with 150-bp reads. Alignment was done with Burrows--Wheeler alignment (BWA)-MEM against the human reference hg19 ([@MEIBNERMCS001677C75]). DNA alignments were processed according to GATK best practices steps ([@MEIBNERMCS001677C76]). GATK HaplotypeCaller version 3.3-0 and VarScan version 2.3.9 ([@MEIBNERMCS001677C74]) were used to call variants. ANNOVAR was used to annotate the union of the two call sets ([@MEIBNERMCS001677C78]). The phylogenetic network was constructed with Network 5.0.0.0 (Fluxus). Somatic signatures in the primary tumor and the metastatic samples were inferred using the deconstructSigs method ([@MEIBNERMCS001677C77]).

RNA library preparation and targeted capture of libraries with exome baits were performed with the Illumina TruSeq RNA Access kit on two RNA aliquots as technical replicates. Paired-end RNA sequencing was performed on the Illumina NextSeq 500 platform with 76-bp reads. Mapping of RNA reads against the human reference hg19 and generation of gene counts were done using STAR ([@MEIBNERMCS001677C73]). RNA-seq count data were processed and differential expression analysis was performed using the DESeq2 Bioconductor package ([@MEIBNERMCS001677C72]), comparing the two patient tumor samples against a set of 11 in-house generated breast tissue controls. KEGG gene set enrichment analysis on differentially expressed and breast cancer relevant genes was performed using the g:ProfileR Bioconductor package (<https://cran.r-project.org/web/packages/g.ProfileR/index.html>). Drug--gene interactions for up-regulated genes were retrieved from the DGIdb database ([@MEIBNERMCS001677C21]).

A detailed description of samples, NGS, and data analysis methods is available in the [Supplemental Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Somatic variants were reported to COSMIC under COSP identifier COSP42774 ([Supplemental Table 6](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001677/-/DC1)). Raw sequence data were submitted to the NCBI Sequence Read Archive under SRA BioProject ID PRJNA358250, BioSample IDs SAMN06168104, SAMN06168105, and SAMN06168106.
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